effect overlay
activetrials
Movement Disorders

A single arm, open-label, phase I study to evaluate the safety and tolerability of ISC-hpNSC injected into the striatum and substantia nigra of patients with Parkinson's disease
 

HREC: 2015.145
Principal Investigator: Dr Andrew Evans
Coordinator contact:
Funding: Commercial
Movement Disorders

An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on NonMotor Symptoms (NMS) in Subjects with Advanced Parkinson's Disease
 

HREC: 2015.171
Principal Investigator: Dr Andrew Evans
Coordinator contact:
Funding: Commercial
Movement Disorders

Bone Health in Recently Diagnosed Patients with Parkinson's Disease Compared to Healthy Age & Sex Matched Controls
 

HREC: 2018.134
Principal Investigator: Dr Andrew Evans
Coordinator contact: Sai Yerra
Funding: Non-Commercial

Proteomics analysis of Parkinson's
 

HREC: 2019.160
Principal Investigator: Dr Andrew Evans
Coordinator contact:
Funding: Non-Commercial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses of Tavapadon in Early Parkinson’s Disease
 

HREC: 2020.027
Principal Investigator: Dr Andrew Evans
Coordinator contact: Fiona Leen
Funding: Commercial